Hoe verhoudt TSHA's PS Ratio zich tot zijn concurrenten?

TSHA is expensive based on its Price-To-Sales Ratio (24.4x) compared to the peer average (20.2x).

Hoe verhoudt TSHA's PS Ratio zich tot andere bedrijven in de US Biotechs industrie?

TSHA is expensive based on its Price-To-Sales Ratio (24.4x) compared to the US Biotechs industry average (12.6x).

Wat is TSHA's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

TSHA is expensive based on its Price-To-Sales Ratio (24.4x) compared to the estimated Fair Price-To-Sales Ratio (20x).

Wat is de reële prijs van TSHA als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Insufficient data to calculate TSHA's fair value for valuation analysis.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Taysha Gene Therapies (Nasdaq:TSHA) - Aandelenkoers, Nieuws & Analyse

TSHA Overzicht aandelen

Taysha Gene Therapies, Inc., een gentherapiebedrijf, richt zich op de ontwikkeling en commercialisering van op adeno-geassocieerd virus gebaseerde gentherapieën voor de behandeling van monogene ziekten van het centrale zenuwstelsel.

Over het bedrijf

TSHA fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 51.85% per year

Risicoanalyse

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Taysha Gene Therapies, Inc. Concurrenten

Ocugen

NasdaqCM:OCGN

US$273.3m

AC Immune

NasdaqGM:ACIU

US$296.8m

Artiva Biotherapeutics

NasdaqGM:ARTV

US$260.4m

Orchard Therapeutics

NasdaqCM:ORTX

US$380.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Taysha Gene Therapies
Historische aandelenkoersen
Huidige aandelenkoers	US$1.53
52 Week Hoogtepunt	US$4.32
52 Week Laag	US$1.27
Bèta	0.38
11 maand verandering	-23.88%
3 maanden verandering	-28.84%
1 Jaar Verandering	-37.04%
33 jaar verandering	-89.99%
5 jaar verandering	n/a
Verandering sinds IPO	-93.64%

Recent nieuws en updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Rendement voor aandeelhouders

	TSHA	US Biotechs	US Markt
7D	-22.3%	-0.7%	-1.6%
1Y	-37.0%	19.8%	30.8%

Rendement versus industrie: TSHA underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: TSHA underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is TSHA's price volatile compared to industry and market?
TSHA volatility
TSHA Average Weekly Movement	8.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: TSHA has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: TSHA's weekly volatility has decreased from 15% to 9% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2019	52	Sean Nolan	www.tayshagtx.com

Taysha Gene Therapies, Inc., een gentherapiebedrijf, richt zich op de ontwikkeling en commercialisering van adeno-geassocieerde virus-gebaseerde gentherapieën voor de behandeling van monogene ziekten van het centrale zenuwstelsel. Het ontwikkelt voornamelijk TSHA-120 voor de behandeling van reusachtige axonale neuropathie; TSHA-102 voor de behandeling van het syndroom van Rett; TSHA-121 voor de behandeling van de ziekte van CLN7; TSHA-118 voor de behandeling van de ziekte van CLN1; TSHA-105 voor de behandeling van SLC13A5-deficiëntie; TSHA-113 voor de behandeling van tauopathieën; TSHA-106 voor de behandeling van angelman-syndroom; TSHA-114 voor de behandeling van fragiele X-syndroom; en TSHA-101 voor de behandeling van GM2-gangliosidose. Taysha Gene Therapies, Inc. heeft een strategisch partnerschap met The University of Texas Southwestern Medical Center.

Taysha Gene Therapies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Taysha Gene Therapies zich tot de beurswaarde?
TSHA fundamentele statistieken
Marktkapitalisatie	US$313.56m
Inkomsten(TTM)	-US$114.33m
Inkomsten(TTM)	US$12.87m

24.4x

P/S-verhouding

-2.7x

Koers/Winstverhouding

Is TSHA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TSHA resultatenrekening (TTM)
Inkomsten	US$12.87m
Kosten van inkomsten	US$0
Brutowinst	US$12.87m
Overige uitgaven	US$127.21m
Inkomsten	-US$114.33m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.56
Brutomarge	100.00%
Nettowinstmarge	-888.18%
Schuld/Eigen Vermogen Verhouding	34.8%

Hoe presteerde TSHA op de lange termijn?

Bekijk historische prestaties en vergelijking

TSHA Overzicht aandelen

Beloningen

Risicoanalyse

Taysha Gene Therapies, Inc. Concurrenten

NasdaqCM:OCGN

US$273.3m

NasdaqGM:ACIU

US$296.8m

NasdaqGM:ARTV

US$260.4m

NasdaqCM:ORTX

US$380.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock